These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25966424)

  • 1. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.
    Kongpetch S; Jusakul A; Ong CK; Lim WK; Rozen SG; Tan P; Teh BT
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):233-44. PubMed ID: 25966424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and transcriptional alterations of cholangiocarcinoma.
    Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics of Opisthorchis viverrini-related cholangiocarcinoma.
    Jusakul A; Kongpetch S; Teh BT
    Curr Opin Gastroenterol; 2015 May; 31(3):258-63. PubMed ID: 25693006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathways of genetic transformation in cholangiocarcinogenesis.
    Serafini FM; Radvinsky D
    Cancer Genet; 2016 Dec; 209(12):554-558. PubMed ID: 27720541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of cholangiocarcinoma carcinogenesis.
    Maemura K; Natsugoe S; Takao S
    J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):754-60. PubMed ID: 24895231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of epigenetic regulation in cholangiocarcinogenesis.
    Zhong B; Liao Q; Wang X; Wang X; Zhang J
    Biomed Pharmacother; 2023 Oct; 166():115290. PubMed ID: 37557012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
    Churi CR; Shroff R; Wang Y; Rashid A; Kang HC; Weatherly J; Zuo M; Zinner R; Hong D; Meric-Bernstam F; Janku F; Crane CH; Mishra L; Vauthey JN; Wolff RA; Mills G; Javle M
    PLoS One; 2014; 9(12):e115383. PubMed ID: 25536104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic alterations associated with cholangiocarcinoma (review).
    Isomoto H
    Oncol Rep; 2009 Aug; 22(2):227-32. PubMed ID: 19578760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
    Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
    Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.
    Capuozzo M; Santorsola M; Landi L; Granata V; Perri F; Celotto V; Gualillo O; Nasti G; Ottaiano A
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic alterations in cholangiocarcinoma-sustained IL-6/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing.
    Isomoto H
    Digestion; 2009; 79 Suppl 1():2-8. PubMed ID: 19153483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma.
    Dong LQ; Shi Y; Ma LJ; Yang LX; Wang XY; Zhang S; Wang ZC; Duan M; Zhang Z; Liu LZ; Zheng BH; Ding ZB; Ke AW; Gao DM; Yuan K; Zhou J; Fan J; Xi R; Gao Q
    J Hepatol; 2018 Jul; 69(1):89-98. PubMed ID: 29551704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathogenesis of cholangiocarcinoma.
    Rizvi S; Gores GJ
    Dig Dis; 2014; 32(5):564-9. PubMed ID: 25034289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and molecular abnormalities in cholangiocarcinogenesis.
    Hassid VJ; Orlando FA; Awad ZT; Tan D; Khoury T; Ahmed BH; Alrawi SJ
    Anticancer Res; 2009 Apr; 29(4):1151-6. PubMed ID: 19414358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
    Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
    Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
    Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
    Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
    J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation spectrum associated with metastasis of advanced cholangiocarcinoma.
    Song H; Huang Y; Jiang X
    J Int Med Res; 2022 Jun; 50(6):3000605221102080. PubMed ID: 35726602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of KRAS and TP53 in a minor proportion of Opisthorchis viverrini-associated cholangiocarcinomas in a hamster model.
    Tangkawattana S; Kaewkes S; Pairojkul C; Tangkawattana P; Sripa B
    Asian Pac J Cancer Prev; 2008; 9(1):101-6. PubMed ID: 18439086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.